Contact us Demo our platform

Dihydroceramide

Dihydroceramide

Linear Formula

C19H39NO3

Synonyms

DHC, DCER, DhCer

Share this metabolite

Dihydroceramides are a group of molecules containing a sphingosine backbone and a fatty acyl chain of various potential lengths. They are the precursors of ceramides, central molecules in sphingolipid metabolism. As amphipathic molecules, dihydroceramides have both hydrophobic and hydrophilic properties and are components of the plasma membrane. Together with membrane-bound protein complexes governing their synthesis, dihydroceramides play various roles in cellular stress responses, cell proliferation and cell death, and a variety of diseases.

Dihydroceramide, ceramide synthase, and sphingolipid metabolism

De novo ceramide synthesis begins in the endoplasmic reticulum, where the amino acid L-serine and palmitoyl-CoA are converted to dihydroceramide via a chain of reactions. The final step of the de novo synthesis pathway is the linkage of one of a variety of fatty acids to sphinganine by (dihydro)ceramide synthase (CerS) to produce dihydroceramide1. Six different CerS enzymes can catalyze the reduction of dihydroceramide to ceramide, depending on the length of the fatty acid chain bound to sphinganine. Each enzyme exhibits tissue specificity; for example, CerS2 shows the highest overall expression levels in all tissues, while CerS1 is mostly present in the brain, skeletal muscle, and testis2.

Once dihydroceramide is produced, it can be reduced to ceramide by the enzyme dihydroceramide desaturase (DES), resulting in a pool of ceramides available for de novo sphingolipid biosynthesis in the Golgi apparatus. There are two DES enzymes, each with distinct tissue specificity. Notably, DES1, which is expressed in most tissues, also functions as an oxygen sensor, thus playing a role in managing systemic hypoxia3.

Dihydroceramides and plasma membrane integrity

Dihydroceramides play an important role in cell membrane integrity. Cell membranes containing ceramide are more fluid than membranes containing dihydroceramides as an additional double bond affects their elasticity and packing ability. Additionally, ceramide molecules can stack on top of each other in an anti-parallel way, forming barrel-like structures. These channels can fill with water and perforate the mitochondrial membrane, eventually leaking mitochondrial proteins and leading to the loss of membrane integrity4. In contrast, dihydroceramides do not form such membrane channels and even hinder their formation. Furthermore, altered levels of dihydroceramides change the compositions of membrane lipids of organelles, which provoke responses at cellular and tissue levels.

Dihydroceramides, oxidative stress, and apoptotic cell death

Systemic hypoxia and oxidative stress inhibit DES1, causing dihydroceramide to accumulate in cells. This accumulation is thought to inhibit cell cycle progression as part of the general response to hypoxia5. The accumulation of dihydroceramide not only inhibits cell cycle progression but also inhibits cell growth, affecting cell division rates and potentially leading to cell cycle arrest as part of the cellular response to oxidative stress. Additionally, when cells encounter stress, ceramide levels rise and the ceramide-to-dihydroceramide-ratio shifts6. The resulting perforation of the mitochondrial outer membrane due to the ceramide channels allows for the release of pro-apoptotic proteins, like cytochrome c and adenylate kinase, into the cytosol. Together with protein kinase C and tumor necrosis factor alpha signaling, this abruptly and irreversibly triggers apoptotic cell death; a process implicated in normal physiology but also in various disease processes4.

Dihydroceramides and disease

Several pathological states, including inflammation, tumorigenesis, and the progression of cancer cells and tumor growth, are accompanied by systemic hypoxia and oxidative stress. This has led to a growing body of research into the connections between dihydroceramides and disease, particularly their role in promoting cytotoxic autophagy in cancer cells and inhibiting tumor growth. For example, studies have demonstrated that dihydroceramides, through their regulation of reactive oxygen species and lipid metabolism, impact β-amyloid secretion and production in Alzheimer’s disease3. Additionally, dihydroceramides are involved in modulating immune responses, linking cellular stress to inflammation and the regulation of cytokine-induced inflammation.

Dihydroceramides and cancer cells

The ability of dihydroceramides to promote cell cycle arrest is relevant in cancer research, particularly for patients with breast cancer7. One potential focus is CerS, as their expressions depend on the type, stage, and grade of the breast tumor and the resulting ceramide species having both positive and negative impacts on tumor growth2. Additionally, preliminary studies showed that treating glioma cells with a sphingosine kinase inhibitor as well as human head and neck squamous carcinoma cells with photodynamic therapy led to elevated dihydroceramide levels inhibiting cell growth3. Similarly, inhibiting DES in human neuroblastoma cells prevents the desaturation of dihydroceramide. Accumulated dihydroceramides subsequently promote cytotoxic autophagy, rendering DES another potential target to treat cancer cells8.

Cardiometabolic diseases

In the context of cardiometabolic diseases, the impairment of insulin signaling due to altered dihydroceramide levels has been linked to insulin resistance, further complicating the management of diabetes and cardiovascular complications of obesity. Research studies found the four 18:0, 20:0, 22:0, 24:1 dihydroceramide species to be associated with waist circumference, a marker for lipid accumulation and obesity8. Increased levels of 18:0, 20:0, 22:0, 23:0, and 24:0 dihydroceramides were also shown to be predictors of insulin sensitivity and type 2 diabetes onset3. Studies in rodents further demonstrated that inhibiting DES in adipocytes result in oxidative stress, cell death, and accumulated dihydroceramides and lipids, impairing adipocyte differentiation and function9. Yet, their roles in inducing insulin resistance, insulin sensitivity and hypertension are not well understood.

Infectious diseases

As an integral part of lipid membranes, dihydroceramides play important roles in viral and bacterial infection processes. Pharmacological inhibition of DES1 results in the accumulation of dihydroceramides and their conversion into dihydrosphingomyelin. This molecule rigidifies the cell membrane, and research has shown that this prevents the integration of an HIV-1 docking peptide, blocking HIV-1 infection10.

Several species of oral bacteria, including Porphyromonas gingivalis, Bacteroides spp, Parabacteroides spp, Tannerella spp, and Prevotella spp produce both free and phosphorylated dihydroceramides, such as phosphoethanolamine and phosphoglycerol dihydroceramides. These sphingolipids play important roles in bacterial resistance to reactive oxidative species and in disease progression. For example, phosphorylated dihydroceramides were shown to penetrate osteoclasts and enhance osteoclastogenesis, triggering the breakdown of gum and bone tissue and promoting periodontitis11.

Dihydroceramide in research

As of April 2024, there are over 960 citations for “dihydroceramide” and 860 citations for “dihydroceramide synthesis” in research publications (excluding books and documents) on Pubmed. Several research publications in the last few years have linked this metabolite to a broad range of physiological functions, many of which are discussed here. Hence, any research program seeking to better understand metabolic and neurological health as well as the underlying molecular mechanisms of tumorigenesis and programmed cell death may benefit from the quantitative analysis of this metabolite.

References

  1. National Library of Medicine, National Center for Biotechnology Information. PubChem Compound Summary, N,N-dimethylarginine (CID 743123831). https://pubchem.ncbi.nlm.nih.gov/compound/123831
  2. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97(5). doi:10.1161/01.RES.0000181286.44222.61
  3. Leone A, Moncada S, Vallance P, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-575. doi:10.1016/0140-6736(92)90865-Z
  4. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscle Thromb Vasc Biol. 2003;23(8):1455-1459. doi:10.1161/01.ATV.0000081742.92006.59
  5. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13(2):490-496. doi:10.1681/ASN.V132490
  6. Wells SM, Buford MC, Migliaccio CT, et al. Elevated Asymmetric Dimethylarginine Alters Lung Function and Induces Collagen Deposition in Mice. Am J Respir Cell Mol Biol. 2009;40(2):179. doi:10.1165/RCMB.2008-0148OC
  7. Vögeli A, Ottiger M, Meier MA, et al. Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Lung. 2017;195(6):717-727. doi:10.1007/S00408-017-0047-9
  8. Wu Y, Shen S, Chen J, et al. Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis. Sci Adv. 2023;9(6). doi:10.1126/SCIADV.ADE5584
  9. Singh I, Kim J, Saxena N, et al. Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis. Immunology. 2021;164(3):602-616. doi:10.1111/IMM.13396
  10. Mortensen KM, Itenov TS, Hansen MB, et al. Mortality in critical illness: The impact of asymmetric dimethylarginine on survival-A systematic review and meta-analysis. Acta Anaesthesiol Scand. 2019;63(6):708-719. doi:10.1111/AAS.13339
  11. Aggarwal S, Gross CM, Kumar S, et al. Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury. Am J Respir Cell Mol Biol. 2014;50(3):614-625. doi:10.1165/RCMB.2013-0193OC
  12. Sozio E, Hannemann J, Fabris M, et al. The role of asymmetric dimethylarginine (ADMA) in COVID-19: association with respiratory failure and predictive role for outcome. Sci Rep. 2023;13(1):1-10. doi:10.1038/s41598-023-36954-z
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.